ClinicalTrials.gg
CompletedNCT01646320Updated Jun 22, 2016Results posted

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

A Phase 3 interventional study of Dapagliflozin and Placebo matching with Dapagliflozin in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 67 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
43rd of 180
320 · median 82
Started
2012
with 4 others
Phase 3
47 of 180
4 open now
Registered
44th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 43rd largest by enrollment, is one of 5 that started in 2012, is one of 47 in phase 3, and was the 44th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to learn if BMS-512148 (Dapagliflozin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.

Read the detailed description

Prior to randomization, all eligible subjects will receive open-label treatment with Saxagliptin 5mg and Metformin IR during the 16-week open-label treatment period.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  1. Signed Written

    1. Subjects must be willing and able to give signed and dated written informed consent.
  2. Target Population

    For inclusion into Stratum A:

    i) Subjects with T2DM with inadequate glycemic control, defined as central laboratory ≥ 8.0 and ≤ 11.5% obtained at the screening visit (ie Week -18 visit), on stable metformin therapy alone for at least 8 weeks prior to screening visit at a dose ≥ 1500 mg per day

    For inclusion into Stratum B:

    ii) Subjects with T2DM with inadequate glycemic control, and HbA1c ≥ 7.5 and ≤ 10.5% obtained at the screening visit and on stable metformin therapy at a dose ≥ 1500 mg per day AND a DPP4 inhibitor at the maximum approved dose for at least 8 weeks prior to screening visit.

    b) C-peptide ≥ 1.0 ng/mL (0.34 nmol/L) at screening visit. c) ≤ 45.0 kg/m2 at the screening visit.

  3. Age and Reproductive Status

    1. Men and women, aged ≥ 18 years old at time of screening visit.
    2. Women of (WOCBP) must be using an acceptable method of to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized.
    3. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of product.
    4. Women must not be breastfeeding
    5. Sexually active fertile men must use highly effective birth control if their partners are WOCBP.

Exclusion Criteria

  1. Target Disease Exceptions

    1. History of diabetes insipidus
    2. Symptoms of poorly controlled diabetes that would preclude participation in this trial including but not limited to marked polyuria and polydipsia with greater than 10% weight loss during the three months prior to screening, or other signs and symptoms.
    3. History of diabetic ketoacidosis or hyperosmolar nonketotic coma.
  2. Medical History and Concurrent Diseases

    1. History of bariatric surgery or lap-band procedure within 12 months prior to screening.
    2. Any unstable endocrine, psychiatric or rheumatic disorders as judged by the Investigator.
    3. Subject who, in the judgment of the investigator, may be at risk for dehydration or volume depletion that may affect the interpretation of efficacy or safety data and concomitant use of loop diuretics in countries where this is not recognized in the Dapagliflozin label.
    4. Subject is currently abusing alcohol or other drugs or has done so within the last 6 months.

      Acute Vascular Event:

    5. Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 160 mmHg and/or diastolic blood pressure (DBP) ≥ 100 mmHg.
    6. Cardiovascular Disease within 3 months of the screening visit [ie myocardial infarction, cardiac surgery or revascularization (CABG/PTCA), unstable angina, stroke or (TIA)].
    7. Congestive heart failure as New York Association () class IV, unstable or acute congestive heart failure.

      Renal Diseases:

    8. Moderate or severe impairment of renal function [defined as \< 60 mL/min/1.73m2 (estimated by MDRD) or serum creatinine (Scr) ≥ 1.5 mg/dL in males or ≥ 1.4 mg/dL in females.]
    9. Conditions of congenital renal glucosuria

      Hepatic Diseases:

    10. Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency, including subjects with and/or AST > 3x and or Total > 2.5 x ULN.

      Hematological and Oncological Disease/Conditions:

    11. History of hemoglobinopathy, with the exception of sickle cell trait (SA) or thalassemia minor; or chronic or recurrent hemolysis.
    12. within 5 years of the screening visit (with the exception of treated basal cell or treated squamous cell carcinoma)
    13. Known status, including but not limited to, individuals who have undergone organ transplantation or who are positive for the .
    14. Donation of blood or blood products to a blood bank, blood transfusion, or participation in a clinical study requiring withdrawal of > 400 mL of blood during the 6 months prior to the screening visit.

      Prohibited treatment and therapies:

    15. Administration of any antihyperglycemic therapy, other than metformin and DPP4's, for more than 14 days (consecutive or not) during the 12 weeks prior to screening, as well as previous exposure to DPP4 or SGLT-2 inhibitor in any DPP4 or SGLT-2 inhibitor trial is an exclusion criterion.
    16. Current treatment with potent cytochrome P450 3A4/5 inhibitors (in countries where dose adjustment would be required by the dapagliflozin label).
    17. Administration of any other investigational drug or participation in any interventional clinical studies within 30 days of planned screening to this study. Subjects who failed to satisfy all eligibility criteria at screening and did not enter the lead-in or open-label period in CV181-168 or CV181-169 studies specifically, do not need to wait 30 days.
  3. Physical and Laboratory Test Findings

    a) ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for women

    b) Presence of hematuria:

    i) For male subjects being considered for Stratum A: microscopic hematuria present at Week -18 or Week -16 AND no common cause that can be confirmed is exclusionary. Male subjects with a confirmed common cause can be entered into the open-label phase with a documented negative result for hematuria microscopic urinalysis performed by the central laboratory.

    ii) For male subjects being considered for Stratum B: microscopic hematuria present at Week -10 or Week -8 AND no common cause that can be confirmed is exclusionary. Male subjects with a confirmed common cause can be entered into the open-label phase with a documented negative result for hematuria microscopic urinalysis performed by the central laboratory.

    NOTE: Female sub}ects with hematuria can be entered into the open-label phase and be randomized, but should be investigated according to local standards and best clinical practices. (See Appendix 3)

    c) Other central laboratory test findings:

    • Abnormal free T4 values. Abnormal thyroid stimulating hormone (TSH) value at screening will be further evaluated by free T4. Sub}ects with abnormal free T4 values will be excluded.
    • Positive for surface antigen
    • Positive for anti- virus antibody
  4. Allergies and Adverse Drug Reaction

    a) Subjects who have to therapy as outlined in the dapagliflozin and saxagliptin Investigator Brochure, the local dapagliflozin or saxagliptin package insert or the local metformin package insert, including current treatment with potent cytochrome P450 3A4/5 inhibitors (in countries where dose adjustment would be required by the local Onglyza (saxagliptin) label.

  5. Sex and Reproductive Status

    a) Women who are pregnant

  6. Other Exclusion Criteria

    1. Prisoners or subjects who are involuntarily incarcerated
    2. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
    3. Subjects on a commercial weight loss program with ongoing weight loss, or on an intensive exercise program.
    4. Employee of BMS, AstraZeneca (AZ), or their relatives.
    5. Subject with any condition which, in the judgment of the Investigator, may render the subject unable to complete the study or which may pose a significant risk to the subject.
    6. Subject is a participating investigator, study coordinator, employee of an investigator or immediate family member of any of the aforementioned.

      Open Label Treatment Period

      Note: Enrollment of subjects into the open-label (Stratum A) treatment period, beginning eee -16 of the study with HbA1c values at the lower bound (≥ 8.0% and ≤ 9.0%) and Enrollment of subjects into the open-label (Stratum B) eee -8, of the study with HbA1c values at the lower bound (≥ 7.5% and ≤ 8.5%) will be limited to approximately 50% of the total number of subjects randomized.

      • For subject in Stratum A:
      • At Week -10 and Week -2 a FPG qualification check will be performed. Subjects with a central laboratory FPG value meeting > 270 mg/dL will be scheduled for a follow-up visit (within 3 - 5 days) to obtain a second central laboratory FPG value. If the mean of the originally scheduled central laboratory FPG and the repeat central laboratory FPG value is > 270 mg/dL, the subject cannot be randomized and must be discontinued.

        • For subjects in Stratum B:
      • At Week -2 a FPG qualification check will be performed. Subjects with a central laboratory FPG value meeting > 270 mg/dL will be scheduled for a follow-up visit (within 3 - 5 days) to obtain a second central laboratory FPG value. If the mean of the originally scheduled central laboratory FPG and the repeat central laboratory FPG value is > 270 mg/dL, the subject cannot be randomized and must be discontinued

      Double Blind Treatment Period

      Inclusion criteria:

      • For Stratum A AND Stratum B:
      • Subjects with T2DM with inadequate glycemic control, defined as central laboratory HbA1c ≥ 7.0 and ≤ 10.5% obtained at the Week -2 visit of the open-label treatment period.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
320 participants (actual)

Study arms

  • Experimental
    Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR

    Drug: Dapagliflozin · Drug: Saxagliptin · Drug: Metformin immediate release (IR)

  • Experimental
    Arm 2: Placebo + Saxagliptin + Metformin IR

    Drug: Placebo matching with Dapagliflozin · Drug: Saxagliptin · Drug: Metformin immediate release (IR)

Interventions

  • Tablets, Oral, 10 mg, Once daily, Up to 52 weeks

  • DrugPlacebo matching with Dapagliflozin

    Tablets, Oral, 0 mg, Once daily, Up to 52 weeks

  • Tablets, Oral, 5 mg, Once daily, Up to 52 weeks

    Also known as: Onglyza

  • DrugMetformin immediate release (IR)

    Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24

    HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period.

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24

    Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period

    Time frame: From Baseline to Week 24

  2. Adjusted Mean Change From Baseline in 120-minute Postprandial Glucose (PPG) at Week 24

    2-hour postprandial glucose (PPG) from a liquid meal tolerance test (2-h MTT) Subject must be fasted for at least 8 hrs prior to the MTT.

    Time frame: From Baseline to Week 24

  3. Adjusted Mean Change From Baseline in Body Weight at Week 24

    Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weights were measured during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period.

    Time frame: From baseline to Week 24

  4. Percentage of Subjects Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])

    Percent adjusted for baseline HbA1c. Therapeutic glycemic response is defined as HbA1c \<7.0%. Data after rescue medication was excluded from this analysis.

    Time frame: From baseline to week 24

07

Results

Posted Apr 11, 2016

Participant flow

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial with Dapagliflozin added to Saxagliptin in Combination with Metformin compared to placebo added to Saxagliptin in combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin and Saxagliptin

Short-term Period (Day 1 to Week 24)
Participant flow — Short-term Period (Day 1 to Week 24)
MilestoneDapa+Saxa+MetPla+Saxa+Met
Started160160
Completed148153
Not completed127
Withdrew: Adverse event30
Withdrew: No longer meets study criteria01
Withdrew: Not reported22
Withdrew: Other10
Withdrew: Lost to follow-up44
Withdrew: Withdrawal by subject20
Long-term Period (Weeks 24 to 52)
Participant flow — Long-term Period (Weeks 24 to 52)
MilestoneDapa+Saxa+MetPla+Saxa+Met
Started147147
Completed141140
Not completed67
Withdrew: Subject no longer meets study criteria20
Withdrew: Withdrawal by subject02
Withdrew: Adverse event42
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up02

Outcome measures

PrimaryAdjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24

HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · Percentage of glycosylated hemoglobin
Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24
Percentage of glycosylated hemoglobinDapa+Saxa+MetPla+Saxa+Met
Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24-0.82 ± 0.0686-0.1 ± 0.0704
Statistical analysis
  • Dapa+Saxa+Met vs Pla+Saxa+Met · Longitudinal Repeated Measures Analysis · p = <0.0001 (Tested at alpha=0.05) · Mean difference (final values): -0.72 · 95% CI -0.91 to -0.53
SecondaryAdjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24

Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · mg/dL
Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24
mg/dLDapa+Saxa+MetPla+Saxa+Met
Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24-32.7 ± 2.821-5.3 ± 2.968
Statistical analysis
  • Dapa+Saxa+Met vs Pla+Saxa+Met · Longitudinal Repeated Measures Analysis · p = <0.0001 (Secondary end points are tested following a sequential testing procedure at alpha=0.05) · Mean difference (final values): -27.5 · 95% CI -35.4 to -19.6
SecondaryAdjusted Mean Change From Baseline in 120-minute Postprandial Glucose (PPG) at Week 24

2-hour postprandial glucose (PPG) from a liquid meal tolerance test (2-h MTT) Subject must be fasted for at least 8 hrs prior to the MTT.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · mg/dL
Adjusted Mean Change From Baseline in 120-minute Postprandial Glucose (PPG) at Week 24
mg/dLDapa+Saxa+MetPla+Saxa+Met
Adjusted Mean Change From Baseline in 120-minute Postprandial Glucose (PPG) at Week 24-73.5 ± 4.055-38.0 ± 4.104
Statistical analysis
  • Dapa+Saxa+Met vs Pla+Saxa+Met · Longitudinal Repeated Measures Analysis · p = <0.0001 (Secondary end points are tested following a sequential testing procedure at alpha=0.05) · Mean difference (final values): -35.5 · 95% CI -46.3 to -24.7
SecondaryAdjusted Mean Change From Baseline in Body Weight at Week 24

Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weights were measured during the qualification and lead-in periods and on Day 1 and Weeks 6, 12, 18, and 24 in the double-blind period.

Time frame:
From baseline to Week 24
Reported as:
Least squares mean · kg
Adjusted Mean Change From Baseline in Body Weight at Week 24
kgDapa+Saxa+MetPla+Saxa+Met
Adjusted Mean Change From Baseline in Body Weight at Week 24-1.91 ± 0.2191-0.41 ± 0.2270
Statistical analysis
  • Dapa+Saxa+Met vs Pla+Saxa+Met · Longitudinal Repeated Measures Analysis · p = <0.0001 (Secondary endpoints are tested following a sequential testing procedure at alpha=0.05) · Mean difference (final values): -1.50 · 95% CI -2.12 to -0.89
SecondaryPercentage of Subjects Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])

Percent adjusted for baseline HbA1c. Therapeutic glycemic response is defined as HbA1c \<7.0%. Data after rescue medication was excluded from this analysis.

Time frame:
From baseline to week 24
Reported as:
Number · Percentage of subjects
Percentage of Subjects Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])
Percentage of subjectsDapa+Saxa+MetPla+Saxa+Met
Percentage of Subjects Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])36.713.3
Statistical analysis
  • Dapa+Saxa+Met vs Pla+Saxa+Met · Modified logistic regression · p = <0.0001 (Secondary end points are tested following a sequential testing procedure at alpha=0.05) · Mean difference (final values): 25.5 · 95% CI 16.7 to 34.4

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DAPA + SAXA + MET—7/160 (4.4%)103/160 (64.4%)
PLA + SAXA + MET—4/160 (2.5%)112/160 (70%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventDAPA + SAXA + METPLA + SAXA + MET
THROMBOCYTOPENIABlood and lymphatic system disorders1/1600/160
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/1600/160
ANGINA UNSTABLECardiac disorders1/1600/160
ATRIAL FIBRILLATIONCardiac disorders1/1600/160
CARDIAC FAILURECardiac disorders1/1600/160
CARDIAC FAILURE ACUTECardiac disorders1/1600/160
VENTRICULAR TACHYCARDIACardiac disorders1/1600/160
GASTRIC ULCERGastrointestinal disorders0/1601/160
ABSCESS LIMBInfections and infestations0/1601/160
APPENDICITISInfections and infestations1/1600/160
Most frequent other events
Showing 10 of 24
Most frequent other events
EventDAPA + SAXA + METPLA + SAXA + MET
URINARY TRACT INFECTIONInfections and infestations15/16016/160
HEADACHENervous system disorders11/16013/160
INFLUENZAInfections and infestations12/16012/160
BACK PAINMusculoskeletal and connective tissue disorders5/16010/160
DIARRHOEAGastrointestinal disorders7/1609/160
HYPERTRIGLYCERIDAEMIAMetabolism and nutrition disorders5/1609/160
NAUSEAGastrointestinal disorders4/1608/160
NASOPHARYNGITISInfections and infestations5/1608/160
VULVOVAGINAL MYCOTIC INFECTIONInfections and infestations7/1601/160
DYSLIPIDAEMIAMetabolism and nutrition disorders7/1603/160

Baseline characteristics

All randomized subjects who received at least one dose of study medication

Age, Continuous
Age, Continuous(YEARS)Dapa+Saxa+MetPla+Saxa+MetTotal
Mean55.2 ± 8.6155.0 ± 9.6055.1 ± 9.10
Age, Customized
Age, Customized(Participants)Dapa+Saxa+MetPla+Saxa+MetTotal
< 65 years137132269
>= 65 years232851
Sex: Female, Male
Sex: Female, Male(Participants)Dapa+Saxa+MetPla+Saxa+MetTotal
Female9084174
Male7076146
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapa+Saxa+MetPla+Saxa+MetTotal
ASIAN112
BLACK/AFRICAN AMERICAN81018
OTHER123
WHITE150147297
AMERICAN INDIAN/ALASKA NATIVE000
NATIVE HAWAIIAN/OTHER PACIFIC ISLANDER000
08

Study locations

67 sites
  • University Of Alabama At Birmingham
    Birmingham, Alabama 35294, United States
  • Clinical Research Advantage Inc/Desert Clinical Research Llc
    Mesa, Arizona 85213, United States
  • Clinical Research Advantage, Inc.
    Phoenix, Arizona 85018, United States
  • Elite Clinical Studies, Llc
    Phoenix, Arizona 85018, United States
  • Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
  • Torrance Clinical Research Institute Inc.
    Lomita, California 90717, United States
  • Randall G. Shue, Do, Inc.
    Los Angeles, California 90023, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Diabetes Medical Center Of California
    Northridge, California 91325, United States
  • Cassidy Medical Group/Clinical Research Advantage
    Vista, California 92083, United States
  • Palm Springs Research Institute
    Hialeah, Florida 33012, United States
  • Fpa Clinical Research
    Kissimmee, Florida 34741, United States
  • International Research Associates, Llc
    Miami, Florida 33183, United States
  • Omega Research Consultants, Llc
    Orlando, Florida 32804, United States
  • Compass Research East, Llc
    Oviedo, Florida 32765, United States
  • Palm Harbor Medical Associates
    Palm Harbor, Florida 34684, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Clinical Research Advantage
    Evansville, Indiana 47714, United States
  • Associated Internal Medicine Specialists
    Battle Creek, Michigan 49015, United States
  • Jackson Clinic
    Rolling Fork, Mississippi 39159, United States
  • Premier Research
    Trenton, New Jersey 08611, United States
  • Metrolina Internal Medicine
    Charlotte, North Carolina 28204, United States
  • Sterling Research Grp, Ltd.
    Cincinnati, Ohio 45246, United States
  • Endocrine Associates
    Houston, Texas 77004, United States
  • Sam Clinical Research Center
    San Antonio, Texas 78229, United States
  • Tidewater Integrated Medical Research
    Virginia Beach, Virginia 23454, United States
  • Local Institution
    Broumov, 550 01, Czech Republic
  • Local Institution
    Pardubice, 530 02, Czech Republic
  • Local Institution
    Praha 10, 100 00, Czech Republic
  • Local Institution
    Praha 4, 149 00, Czech Republic
  • Local Institution
    Pribram V, 261 95, Czech Republic
  • Local Institution
    Guadalajara, Jalisco 44670, Mexico
  • Local Institution
    Zapopan, Jalisco 45116, Mexico
  • Local Institution
    Zapopan, Jalisco 45200, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64060, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64460, Mexico
  • Local Institution
    Aguascalientes, 20127, Mexico
  • Local Institution
    Bialystok, 15-435, Poland
  • Local Institution
    Krakow, 30-015, Poland
  • Local Institution
    Ruda Slaska, 41-709, Poland
  • Local Institution
    Warszawa, 00-465, Poland
  • Local Institution
    Warszawa, 01-868, Poland
  • Local Institution
    Warszawa, 03-003, Poland
  • Local Institution
    Zory, 44-240, Poland
  • Clinical Research Puerto Rico
    San Juan, 00909, Puerto Rico
  • Local Institution
    Bucharest, 010825, Romania
  • Local Institution
    Bucharest, 070208, Romania
  • Local Institution
    Constanta, 900591, Romania
  • Local Institution
    Craiova, 200349, Romania
  • Local Institution
    Galati, 800098, Romania
  • Local Institution
    Ploiesti, 100097, Romania
  • Local Institution
    Kursk, 305035, Russian Federation
  • Local Institution
    Moscow, 119034, Russian Federation
  • Local Institution
    Saint-petersburg, 194044, Russian Federation
  • Local Institution
    St. Petersburg, 194044, Russian Federation
  • Local Institution
    St. Petersburg, 194156, Russian Federation
  • Local Institution
    St. Petersburg, 195257, Russian Federation
  • Local Institution
    St. Petersburg, 197136, Russian Federation
  • Local Institution
    St.petersburg, 195112, Russian Federation
  • Local Institution
    St.petersburg, 197022, Russian Federation
  • Local Institution
    Yaroslaval, 150062, Russian Federation
  • Local Institution
    Portsmouth, Hants PO3 6LY, United Kingdom
  • Local Institution
    Newport, Isle of Wight PO30 5TG, United Kingdom
  • Local Institution
    Liverpool, Merseyside L7 8XP, United Kingdom
  • Local Institution
    Chippenham, Wiltshire SN15 1HP, United Kingdom
  • Local Institution
    Bedfordshire, SG19 3JR, United Kingdom
  • Local Institution
    London, W6 7HY, United Kingdom
09

References and documents

Publications

  • Mathieu C, Catrinoiu D, Ranetti AE, Johnsson E, Hansen L, Chen H, Garcia-Sanchez R, Iqbal N, Celinski A. Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes. Diabetes Ther. 2018 Aug;9(4):1703-1711. doi: 10.1007/s13300-018-0445-x. Epub 2018 May 25. PubMed 29802530 ↗
  • Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, Chen H, Hansen L, Iqbal N. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. Diabetes Care. 2015 Nov;38(11):2009-17. doi: 10.2337/dc15-0779. Epub 2015 Aug 5. PubMed 26246458 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Aug 2014 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2012
First posted
Jul 20, 2012
Start
Sep 2012
Primary completionActual
Aug 2014
CompletionActual
Feb 2015
Results first posted
Apr 11, 2016
Last update
Jun 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01646320
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 20, 2012
Start date
Sep 2012
Primary completion
Aug 2014
Completion
Feb 2015
Results posted
Apr 11, 2016
Last update
Jun 22, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion